Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06177925CT.gov A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | — | Recruiting | — | — | — |
NCT05904015CT.gov The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC | — | Not Yet Recruiting | — | — | — |
NCT04490421CT.gov Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. | — | Unknown | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04380636CT.gov Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | — | Active Not Recruiting | — | — | — |
NCT01109524CT.gov Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01114958CT.gov Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases | — | Completed | — | — | — |
NCT00657423CT.gov Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT00413283CT.gov Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00174772CT.gov Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00132639CT.gov Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00051506CT.gov ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Nanfang Hospital, Southern Medical University | P3 | B · 62 |
| Carboplatin | Nanfang Hospital, Southern Medical University | P4 | BB |
| Nivolumab | Hospital Israelita Albert Einstein | P2 | BB |
| Belagenpumatucel-L (Sk-Lu-1) | NovaRx Corporation | P3 | BB |
| Icotinib | Fuda Cancer Hospital, Guangzhou | P4 | BB |
| Rivoceranib | Fuzhou General Hospital | P3 | BB |
| Cyclophosphamide | Pfizer | P3 | BB |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | BB |
| Trastuzumab | Cancer Research UK | P2/3 | B |
+39 more in the Lung Neoplasm cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Lung Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-lung-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →